Lewis Bender is Intensity Therapeutics' founder and has served as President and Chief Executive Officer since April 2012. Prior to founding Intensity, Mr. Bender was the CEO of Interleukin Genetics, Inc., a personalized medicine company, from 2008 until 2012. Mr. Bender also held numerous positions including Interim President & CEO and Chief Technology Officer at Emisphere Technologies, Inc., a drug delivery company specializing in the development of oral delivery of poorly absorbed molecules, from 1993 to 2007. Mr. Bender has over 26 years of biotech and pharmaceutical executive management experience, and has led development teams taking products from discovery to Phase 3 for compounds using novel drug delivery techniques. Mr. Bender has a both a BS and MS in Chemical Engineering from The Massachusetts Institute of Technology (MIT), an MBA from the University of Pennsylvania’s Wharton School, and an MA in International Studies also from the University of Pennsylvania. He is fluent in French and German.